SCIENTEX Group is a renowned healthcare focused CBDO presenting 13 international business awards with a global footprint thanks to +110 achieved deals in track record through 38 mandates from our US & EU clients.
SCIENTEX Group, acting as a transition management company dedicated to healthcare startups, is covering mainly financing & business development matters, on sell & buy side: from seed capital to public offerings & follow-on financings, M&A, business development & licensing, R&D partnering.
SCIENTEX has developed 4 products & services in order to boost all corporate activities, by leveraging the track record of its two founders (+110 deals since 1999 including financing, R&D partnering, BusDev & licensing, IPOs, M&A, M&S on both sell & buy sides & 38 missions since 2006 & +26 board member position since 1999) :
Thanks to a highly pragmatic approach fully dedicated to milestones achievments, SCIENTEX's associates are structured to work 60% more (2430 hours/year) than the 1529 hours, average working time in Europe. Thanks to its low cost fees, SCIENTEX will allow its clients to reduce their labor costs compared to FTE. Each of the 2 associates of SCIENTEX are limiting their supports to 2 clients max in parallel in order to guarantee their full intensive, full time , and fully dedicated supports. Generally speaking, for transition management missions, SCIENTEX's associates are supporting operationally CFO+CBO functions on a day to day basis , working remotely and commuting internationally , without any outsourcing.